- Policy
- Korean pharmas are pursuing various SGLT-2 combos
- by Lee, Tak-Sun Aug 30, 2021 05:55am
- Companies are busy developing combination therapies combining the latest diabetes treatment, SGLT-2 inhibitors, with existing diabetes treatment. In particular, domestic companies that are eyeing the SGLT-2 market have been testing various combinations for commercialization. On the 26th, the Ministry of Food and Drug Safety approved the P
- Policy
- The patent for Breast Cancer Therapy Affinitor has been clos
- by Lee, Tak-Sun Aug 30, 2021 05:55am
- The patent suit for Affinitor, which was conducted by Novartis and Kwang Dong, was finally closed due to the plaintiff's withdrawal. As a result, Kwang Dong and Samyang Biopharm are able to market more actively. According to the industry on the 26th, the lawsuit against the use patent of Afinitor, which has been filed since March last year
- Company
- Cosentyx begins competition in the market
- by Aug 30, 2021 05:54am
- As Interleukin-17 (IL-17) sanctions enter the primary biological formulation benefit range for psoriasis arthritis, they will compete in earnest with TNF-α inhibitors. Cosentyx (Secukinumab) of Novartis expanded health insurance benefits from psoriasis arthritis to primary biological sanctions on the 1st. Cosentyx can be used if it meets c
- Policy
- Regulation of COVID-19 vaccines is imminent
- by Lee, Jeong-Hwan Aug 27, 2021 05:59am
- As the "Special Act on the Development of Public Health Crisis Response Medical Products and the Emergency Supply" sub-enforcement decree passed the Regulation Reform Committee preliminary review, regulations and management such as COVID vaccines will be strengthened. The MFDS plans to conduct a follow-up investigation of the public health
- Opinion
- [Reporter’s View]Reimbursement of antidiabetic combos
- by Eo, Yun-Ho Aug 27, 2021 05:59am
- After 3 long years, discussions on extending reimbursement of SGLT-2 inhibitor combos are expected to begin. In September, the Health Insurance Review and Assessment Service will hold an expert meeting to discuss approving reimbursement for combination use of the two classes of oral antidiabetics: DPP-4 inhibitors and SGLT-2inhibitors.
- Company
- Shingles vaccine market overwhelmed by COVID-19… drops 60%
- by An, Kyung-Jin Aug 27, 2021 05:59am
- The domestic market for shingles is shrinking at a fast pace. With vaccinations for COVID-19 ongoing in earnest from earlier this year and the new ‘Delta variant’ intensifying the resurgence of COVID-19 cases, sales of the two shingles vaccines have dropped together. According to the pharmaceutical research institution IQVIA on the 26th, th
- Policy
- RSA refund should be differentiated by income
- by Kim, Jung-Ju Aug 27, 2021 05:59am
- Currently, it has been suggested that Korea should apply RSA's refund flexibly by differentiating it according to income. It is suggested that the government should reduce the refund of high-income earners according to the income distribution and strengthen the guarantee of high-weakness by operating the refund of low-income earners in the form
- Company
- Korea Pharma has signed a contract to supply Accrufer
- by Aug 27, 2021 05:59am
- Korea Pharma announced on Monday that it has signed an exclusive contract with Shield Theapeutics to supply the anaemic drug Accrufer in Korea. Anemia is very common in patients with inflammatory bowel disease (IBD) and chronic kidney disease (CKD). Poor treatment of anemia increases the morbidity and morbidity of cardiovascular disease. A
- Policy
- Clinical trials of Jardiance have been approved
- by Lee, Tak-Sun Aug 26, 2021 05:58am
- The SGLT-2 diabetes treatment has expanded its indication to other treatments for diseases such as heart failure. In Korea, AstraZeneca's Forxiga (Dapagliflozin Propanediol Hydrate) has also been recognized for its efficacy and effect on chronic heart failure and chronic kidney disease. And Boehringer Ingelheim's "Jardiance (Empagliflozin)" i
- Company
- Who will head Novartis Korea after Joshi Venugopal?
- by Eo, Yun-Ho Aug 26, 2021 05:58am
- The president of Novartis Korea is expected to change soon. According to industry sources, Joshi Venugopal, who had led Novartis Korea since September 2018, has completed his term at the end of last month and made a promotional transfer to become the Global Head of New Products at Novartis headquarters. Novartis Korea’s Chief Finance
